ÀüÀ̼º ½ÅÀå¾Ï¿¡ ´ëÇÑ Ç¥Àû Ä¡·áÀÇ ½Ã´ë¿¡¼ ¸é¿ªÄ¡·áÀÇ ¿ªÇÒ
The Role of Immunotherapy in the Era of TKI with Metastatic Renal Cell Carcinoma
Journal of Urologic Oncology 2014³â 12±Ç 2È£ p.59 ~ p.64
À̱â¼ö(Lee Ki-Soo) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
±èÅÂÈ¿(Kim Tae-Hyo) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
Abstract
Treatment of metastatic renal cell cancer (mRCC) is rapidly evolving since evidence concerning efficacy of novel molecular targeted drugs recently became available. But, Tyrosine kinase inhibitors achieve objective response or disease stabilization in a higher proportion of patients, but neither cure nor significant survival advantage has been shown for these agents. The role of conventional immunotherapy is still supported to the some patients in some medical centers. we will show the currently approved options available for these disease processes, including the newer agents and selected combinatorial approaches under investigation, and we attempt to identify the role of high-dose IL-2 in the context of current clinical practice. This paper provides a critical overview of the current and future role of cytokine-based immunotherapy in mRCC in light of these new developments.
Å°¿öµå
Renal cell carcinoma, Metastasis, Immunotherphy
KMID :
1001020140120020059
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)